P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells

被引:65
作者
Guimond, M [1 ]
Balassy, A [1 ]
Barrette, M [1 ]
Brochu, S [1 ]
Perreault, C [1 ]
Roy, DC [1 ]
机构
[1] Univ Montreal, Dept Med, Maisonneuve Rosemont Hosp, Res Ctr,Div Hematol Immunol, Montreal, PQ H3C 3J7, Canada
关键词
D O I
10.1182/blood-2001-12-0353
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
T lymphocytes have been found to harbor P-glycoprotein (Pgp) and to demonstrate modulation of its ion channel transporter function according to the state of activation of T lymphocytes. We hypothesized that cytotoxic chemicals that are extruded by Pgp could be used to specifically eliminate immunoreactive T-cell populations. In this study, we evaluated the capacity of 4,5-dibromorhodamine methyl ester (TH9402), a photosensitizer structurally similar to rhodamine, a dye transported by Pgp, and which becomes highly cytotoxic on activation with visible light to selectively deplete alloreactive T lymphocytes. Stimulation of T cells with mitogens or allogeneic major histocompatibility complex-mismatched cells resulted in the preferential retention of the TH9402 rhodamine-derivative in activated T cells, both CD4(+) and CD8(+). Photodynamic cell therapy of TH9402-exposed T cells led to the selective elimination of immunoreactive T-cell populations. In addition, this treatment preserved resting T cells and their capacity to respond to third-party cells. Inhibition of Pgp enhanced cellular trapping of the dye in nonactivated T cells and resulted in their depletion after exposure to light. Targeting of Pgp-deficient cells may therefore represent an appealing strategy for the prevention and treatment of graft-versus-host disease and other alloimmune or autolmmune disorders. (Blood. 2002;100: 375-382). (C) 2002 by The American Society of Hematology.
引用
收藏
页码:375 / 382
页数:8
相关论文
共 80 条
[11]  
Champlin RE, 2000, BLOOD, V95, P3996
[12]  
CHAUDHARY PM, 1992, BLOOD, V80, P2735
[13]   MULTIDRUG RESISTANCE ACTIVITY IN HUMAN-LYMPHOCYTES [J].
COON, JS ;
WANG, YZ ;
BINES, SD ;
MARKHAM, PN ;
CHONG, ASF ;
GEBEL, HM .
HUMAN IMMUNOLOGY, 1991, 32 (02) :134-140
[14]   DCs and peripheral T cell tolerance [J].
Fazekas de St Groth, B .
SEMINARS IN IMMUNOLOGY, 2001, 13 (05) :311-321
[15]   Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69) [J].
Fehse, B ;
Frerk, O ;
Goldmann, M ;
Bulduk, M ;
Zander, AR .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (03) :644-651
[16]   Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: Considerations for the allogeneic transplantation therapy of leukemia and lymphoma [J].
Fowler, DH ;
Gress, RE .
LEUKEMIA & LYMPHOMA, 2000, 38 (3-4) :221-234
[17]  
French LE, 2001, ARCH DERMATOL, V137, P1309
[18]   Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations [J].
Garderet, L ;
Snell, V ;
Przepiorka, D ;
Schenk, T ;
Lu, JG ;
Marini, F ;
Gluckman, E ;
Andreeff, M ;
Champlin, RE .
TRANSPLANTATION, 1999, 67 (01) :124-130
[19]   BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE - INCREASED RISK FOR RELAPSE ASSOCIATED WITH T-CELL DEPLETION [J].
GOLDMAN, JM ;
GALE, RP ;
HOROWITZ, MM ;
BIGGS, JC ;
CHAMPLIN, RE ;
GLUCKMAN, E ;
HOFFMANN, RG ;
JACOBSEN, SJ ;
MARMONT, AM ;
MCGLAVE, PB ;
MESSNER, HA ;
RIMM, AA ;
ROZMAN, C ;
SPECK, B ;
TURA, S ;
WEINER, RS ;
BORTIN, MM .
ANNALS OF INTERNAL MEDICINE, 1988, 108 (06) :806-814
[20]   Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection [J].
Gratama, JW ;
van Esser, JWJ ;
Lamers, CHJ ;
Toumay, C ;
Löwenberg, B ;
Bolhuis, RLH ;
Cornelissen, JJ .
BLOOD, 2001, 98 (05) :1358-1364